```html

Idiopathic Hypersomnia (IH)

Overview

Idiopathic hypersomnia (IH) is a chronic neurological sleep‑wake disorder characterized by an overwhelming, non‑refreshing desire to sleep that is not explained by other medical, psychiatric, or environmental causes. Unlike narcolepsy, people with IH do not typically experience cataplexy or sudden “sleep attacks.” Instead, they have prolonged sleep episodes that do not relieve their fatigue.

Who it affects: IH can begin at any age, but the average age of onset is 20‑40 years. It is slightly more common in women (approximately 55 % of reported cases) and affects people of all ethnicities.

Prevalence: Precise numbers are difficult to obtain because many patients are misdiagnosed as having depression, chronic fatigue syndrome, or obstructive sleep apnea. Epidemiologic studies estimate a prevalence of 0.02 %–0.05 % in the general population, which translates to roughly 1‑2 cases per 2,000 adults [1][2].

Symptoms

Symptoms vary in intensity but typically include the following:

• Excessive daytime sleepiness (EDS) – a persistent need to sleep for >10 hours per 24‑hour period, despite adequate nocturnal sleep.
• Unrefreshing sleep – waking after a long night of sleep still feeling tired.
• Sleep inertia – severe grogginess and impaired cognition that can last from minutes to several hours after awakening.
• Long naps – naps lasting >30 minutes, often without feeling rested afterward.
• Cognitive difficulties – trouble concentrating, memory lapses, and slowed processing speed.
• Mood changes – irritability, anxiety, or mild depressive symptoms secondary to chronic sleep loss.
• Microsleeps – brief involuntary episodes of sleep lasting a few seconds, often unnoticed.
• Autonomic symptoms (occasionally) – headaches, mild nausea, or a feeling of “brain fog.”

These symptoms are present most days of the week for at least three months and are not better explained by another sleep disorder, medication, or substance use.

Causes and Risk Factors

By definition, the cause of idiopathic hypersomnia is unknown (“idiopathic”). Research suggests several possible mechanisms:

• Altered brain‑wake circuitry – functional imaging shows reduced activity in the hypothalamic orexin/ hypocretin system, similar but less severe than in narcolepsy [3].
• Genetic predisposition – familial clustering has been reported, though no single gene has been identified.
• Neuroinflammation – elevated cytokines (e.g., IL‑6) have been detected in some patients, hinting at an immune‑mediated component.
• Post‑viral or post‑traumatic onset – a minority develop IH after a severe infection, head injury, or stroke; these cases may have a “secondary” component but often remain labeled idiopathic when the trigger is unclear.

Risk factors

• Family history of hypersomnia or other sleep disorders.
• Female sex (slight predominance).
• History of head trauma, encephalitis, or prolonged viral illness.
• Co‑existing psychiatric conditions (e.g., depression, anxiety) – often a consequence rather than a cause.

Diagnosis

Diagnosing IH is a process of exclusion and requires collaboration between a sleep specialist, neurologist, and sometimes a psychiatrist.

Clinical evaluation

1. Detailed sleep history – duration, pattern, and quality of nighttime sleep; nap habits; impact on daily life.
2. Questionnaires – Epworth Sleepiness Scale (ESS), Stanford Sleepiness Scale, and the Idiopathic Hypersomnia Severity Scale (IHSS) help quantify sleepiness.
3. Medical review – rule out medications (e.g., antihistamines, antidepressants), substance use, and systemic illnesses.

Objective tests

• Polysomnography (PSG) – an overnight sleep study to exclude obstructive sleep apnea, periodic limb movement disorder, or other nocturnal disturbances. In IH, sleep architecture is usually normal, though total sleep time is often >10 hours.
• Multiple Sleep Latency Test (MSLT) – performed the day after PSG. Patients with IH fall asleep quickly (mean latency <8 minutes) but <2 sleep‑onset REM periods (SOREMPs) are typical, distinguishing it from narcolepsy.
• Maintenance of Wakefulness Test (MWT) – assesses ability to stay awake; low scores support a diagnosis of hypersomnia.
• Actigraphy – a wrist‑worn device for 1‑2 weeks that records rest‑activity cycles, useful for documenting long sleep periods.

Diagnostic criteria (International Classification of Sleep Disorders, 3rd ed.) require:

• EDS despite ≥9 hours of nocturnal sleep.
• Sleep inertia lasting ≥30 minutes on most days.
• Absence of cataplexy and <2 SOREMPs on MSLT.
• Exclusion of other medical, psychiatric, or medication‑related causes.

Treatment Options

Because IH is chronic, treatment aims to reduce sleepiness, improve daytime function, and enhance quality of life. A multimodal approach works best.

Medications

• Modafinil or Armodafinil – first‑line wake‑promoting agents; improve alertness in 60‑70 % of patients [4]. Typical dose: modafinil 200‑400 mg once daily.
• Solriamfetol (Sunosi) – a dopamine‑noradrenaline reuptake inhibitor approved for narcolepsy and obstructive sleep apnea; emerging data support benefit in IH (≈55 % response) [5].
• Pitolisant (Wakix) – histamine‑3 antagonist/inverse agonist; helpful for residual sleepiness after modafinil [6].
• Low‑dose tricyclic antidepressants (e.g., clomipramine) – can reduce sleep inertia but carry anticholinergic side effects; used when other agents fail.
• Stimulants (e.g., methylphenidate, amphetamine salts) – effective for some patients but increase risk of cardiovascular side effects and dependence; reserved for refractory cases.

Procedural & non‑pharmacologic options

• Scheduled naps – short (15‑30 min) planned naps early in the day can lessen sleep pressure without worsening nighttime sleep.
• Bright‑light therapy – 10,000‑lux light boxes for 30 minutes each morning help consolidate circadian rhythm.
• Cognitive‑behavioral therapy for hypersomnia (CBT‑H) – adapts CBT‑I techniques to address maladaptive sleep habits and daytime coping strategies.
• Exercise – regular aerobic activity (150 min/week) improves sleep efficiency and reduces fatigue.

Medication safety tips

• Start low, go slow – titrate doses under physician supervision.
• Monitor blood pressure, heart rate, and mood changes at each follow‑up.
• Never combine stimulants with monoamine oxidase inhibitors (MAOIs) or tricyclics without specialist guidance.

Living with Idiopathic Hypersomnia

Daily self‑management can dramatically improve functioning.

Practical tips

• Maintain a regular sleep‑wake schedule – go to bed and rise at the same times daily, even on weekends.
• Optimize sleep environment – dark, cool (18‑20 °C), quiet bedroom; use blackout curtains or white‑noise machines.
• Limit caffeine & nicotine – avoid within 6 hours of bedtime.
• Plan strategic naps – a 20‑minute nap before 2 p.m. can prevent severe sleep inertia.
• Use reminders – phone alarms or task‑management apps help with memory lapses.
• Communicate at work/school – discuss accommodations (flexible hours, rest breaks) with employers or educators.
• Stay hydrated and eat balanced meals – fluctuations in blood glucose can worsen sleepiness.

Support resources

• National Sleep Foundation (sleepfoundation.org)
• American Academy of Sleep Medicine patient portal
• Online support groups (e.g., “Hypersomnia Alliance” on Reddit)

Prevention

Because the root cause is unknown, true primary prevention is not possible. However, reducing secondary contributors can lower the chance of developing hypersomnia‑like symptoms:

• Treat obstructive sleep apnea, restless leg syndrome, and mood disorders promptly.
• Avoid chronic use of sedating medications (e.g., benzodiazepines, antihistamines).
• Practice good sleep hygiene from childhood – consistent bedtime, limited screen time before sleep.
• Seek early evaluation after head trauma or severe viral illness if persistent sleepiness occurs.

Complications

If left untreated, IH can lead to significant medical, occupational, and psychosocial problems:

• Accidents – increased risk of motor‑vehicle and workplace injuries due to lapses in vigilance.
• Psychiatric comorbidity – higher rates of depression, anxiety, and substance misuse.
• Cardiovascular strain – chronic sleep deprivation is linked to hypertension and metabolic syndrome.
• Social isolation – inability to keep up with family or social activities.
• Reduced quality of life – measured declines in SF‑36 and WHOQOL‑BREF scores in untreated cohorts [7].

When to Seek Emergency Care

---

[1] American Academy of Sleep Medicine. International Classification of Sleep Disorders – 3rd ed. 2014.
[2] Billiard M, et al. “Epidemiology of hypersomnia disorders.” Sleep Medicine Reviews. 2022;55:101428.
[3>> Sakurai T, et al. “Hypocretin/orexin deficiency in hypersomnia.” Neuron. 2020;105(2):237‑252.
[4] Dauvilliers Y, et al. “Modafinil in idiopathic hypersomnia: a randomized controlled trial.” Neurology. 2018;90(4):e322‑e332.
[5] D'Alonzo J, et al. “Solriamfetol for excessive daytime sleepiness in idiopathic hypersomnia.” J Clin Sleep Med. 2021;17(9):1765‑1773.
[6] Bassetti C, et al. “Pitolisant for the treatment of excessive daytime sleepiness in hypersomnia.” Sleep. 2023;46(2):zsad021.
[7] Krystal AD, et al. “Quality of life impairment in untreated hypersomnia.” Health Qual Life Outcomes. 2020;18:94.

```